$0.05 EPS Expected for Advantage Oil & Gas Ltd (USA) (AAV); Vital Therapies (VTL) Had 3 Bullish Analysts

October 23, 2017 - By wolcottdaily

Analysts expect Advantage Oil & Gas Ltd (USA) (NYSE:AAV) to report $0.05 EPS on November, 2.They anticipate $0.02 EPS change or 66.67% from last quarter’s $0.03 EPS. AAV’s profit would be $9.36M giving it 27.25 P/E if the $0.05 EPS is correct. After having $0.06 EPS previously, Advantage Oil & Gas Ltd (USA)’s analysts see -16.67% EPS growth. It closed at $5.45 lastly. It is down 17.34% since October 23, 2016 and is uptrending. It has outperformed by 0.64% the S&P500.

Among 7 analysts covering Vital Therapies Inc (NASDAQ:VTL), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Vital Therapies Inc had 11 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Tuesday, September 29 by SunTrust. BTIG Research initiated Vital Therapies Inc (NASDAQ:VTL) rating on Friday, August 7. BTIG Research has “Buy” rating and $23 target. Canaccord Genuity maintained the shares of VTL in report on Monday, August 24 with “Buy” rating. The firm has “Outperform” rating given on Monday, August 10 by Credit Suisse. The rating was downgraded by Suntrust Robinson on Monday, August 24 to “Neutral”. The firm earned “Neutral” rating on Monday, October 26 by BTIG Research. The rating was downgraded by SunTrust to “Buy” on Monday, August 24. The stock of Vital Therapies Inc (NASDAQ:VTL) earned “Neutral” rating by Suntrust Robinson on Tuesday, September 29. On Monday, August 24 the stock rating was downgraded by William Blair to “Outperform”. On Monday, August 24 the stock rating was downgraded by Credit Suisse to “Neutral”. See Vital Therapies Inc (NASDAQ:VTL) latest ratings:

19/05/2017 Broker: Raymond James Rating: Outperform New Target: $6.00 Initiates Coverage On

Since June 6, 2017, it had 8 buys, and 0 insider sales for $323,955 activity. 30,000 Vital Therapies Inc (NASDAQ:VTL) shares with value of $93,306 were bought by Satter Muneer A. $12,182 worth of Vital Therapies Inc (NASDAQ:VTL) was bought by Nash Duane. Shares for $48,069 were bought by BIENAIME JEAN JACQUES on Tuesday, June 13. $7,724 worth of Vital Therapies Inc (NASDAQ:VTL) shares were bought by DUNN JOHN MICHAEL. Winters Terence E. also bought $30,981 worth of Vital Therapies Inc (NASDAQ:VTL) shares. 2,000 shares were bought by Ashley Robert A., worth $6,360.

It closed at $5.75 lastly. It is down 61.75% since October 23, 2016 and is downtrending. It has underperformed by 78.45% the S&P500.

Investors sentiment decreased to 0.76 in Q2 2017. Its down 0.39, from 1.15 in 2017Q1. It turned negative, as 12 investors sold Vital Therapies Inc shares while 17 reduced holdings. 12 funds opened positions while 10 raised stakes. 10.19 million shares or 4.05% less from 10.62 million shares in 2017Q1 were reported. Ironwood Ltd Limited Liability Company invested in 860 shares or 0% of the stock. Bnp Paribas Arbitrage Sa holds 0% or 939 shares in its portfolio. Legal And General Gru Public Limited Com owns 1,896 shares or 0% of their US portfolio. Bankshares Of Ny Mellon Corporation holds 0% or 25,773 shares. Susquehanna Interest Grp Ltd Liability Partnership has 0% invested in Vital Therapies Inc (NASDAQ:VTL) for 92,364 shares. Granahan Inv Management Ma reported 0.07% in Vital Therapies Inc (NASDAQ:VTL). Jpmorgan Chase And has 1,221 shares for 0% of their portfolio. Vanguard Grp holds 738,521 shares or 0% of its portfolio. Creative Planning invested 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). Credit Suisse Ag invested in 61,120 shares or 0% of the stock. Art Advisors Lc owns 18,200 shares. Manufacturers Life Insur The, a Ontario - Canada-based fund reported 996 shares. State Street Corp holds 0% or 66,849 shares in its portfolio. Deutsche Bancorp Ag reported 0% of its portfolio in Vital Therapies Inc (NASDAQ:VTL). Bancorp Of America Corporation De invested 0% in Vital Therapies Inc (NASDAQ:VTL).

Vital Therapies, Inc. is a biotherapeutic company. The company has market cap of $242.69 million. The Firm is focused on developing a human hepatic cell treatment targeting acute forms of liver failure. It currently has negative earnings. The Company’s product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Among 4 analysts covering Advantage Oil & Gas Ltd. (NYSE:AAV), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Advantage Oil & Gas Ltd. had 10 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Thursday, July 21 by TD Securities. BMO Capital Markets initiated the stock with “Outperform” rating in Thursday, July 21 report. The firm earned “Outperform” rating on Friday, October 14 by Credit Suisse. TD Securities maintained the stock with “Buy” rating in Friday, August 7 report. BMO Capital Markets downgraded the shares of AAV in report on Tuesday, October 10 to “Market Perform” rating. RBC Capital Markets maintained the shares of AAV in report on Monday, August 8 with “Outperform” rating. RBC Capital Markets downgraded Advantage Oil & Gas Ltd (USA) (NYSE:AAV) on Thursday, July 20 to “Sector Perform” rating.

Advantage Oil & Gas Ltd. is an intermediate natural gas and liquids development and production company. The company has market cap of $1.02 billion. The Firm is engaged in the business of natural gas exploitation, development, acquisition and production in the Province of Alberta. It has a 21.67 P/E ratio. The Firm focuses on the development of Montney resource play at Glacier, Alberta in Western Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com